Article
FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML.
Bone marrow transplantation - 1 Apr 2016
Song Yeohan, Magenau John, Li Yumeng, Braun Thomas, Chang Lawrence, Bixby Dale, Hanauer David A, Chughtai Komal A, Gatza Erin, Couriel Daniel, Goldstein Steven, Pawarode Attaphol, Reddy Pavan, Riwes Mary, Connelly James, Harris Andrew, Kitko Carrie, Levine John, Yanik Greg, Parkin Brian, Choi Sung Won
Abstract excerpt
Allogeneic hematopoietic cell transplantation (HCT) has been increasingly used in the setting of FMS-like tyrosine kinase-3 (FLT3)-mutated AML. However, its role in conferring durable relapse-free intervals remains in question. Herein we sought to investigate FLT3 mutational status on transplant outcomes. We conducted a retrospective cohort study of 262 consecutive AML patients who underwent first-time allogeneic...
Topics
- Adolescent
- Adult
- Aged
- Allografts
- Child
- Child, Preschool
- Disease-Free Survival
- Female
- Hematopoietic Stem Cell Transplantation